AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceNamed GroupsHealth CareGeographicals
NeutropeniaFebrile NeutropeniaChemotherapy-Induced Febrile NeutropeniaAntineoplastic Combined Chemotherapy ProtocolsFeverMortalityTreatment OutcomeTaxoidsChemotherapy, AdjuvantDrug Administration ScheduleGranulocyte Colony-Stimulating FactorNeoplasmsAntineoplastic AgentsCisplatinSurvival AnalysisPaclitaxelSurvival RateDoxorubicinCyclophosphamideInfusions, IntravenousDisease-Free SurvivalDeoxycytidineCombined Modality TherapyHospital MortalityLung NeoplasmsVinblastineProspective StudiesAntineoplastic Agents, PhytogenicBreast NeoplasmsInfant MortalityCamptothecinCarboplatinRetrospective StudiesTime FactorsPrognosisAgranulocytosisNeoplasm StagingMaximum Tolerated DoseFollow-Up StudiesEtoposideMycosesCause of DeathFever of Unknown OriginOrganoplatinum CompoundsIfosfamideThrombocytopeniaHematologic NeoplasmsDose-Response Relationship, DrugHematologic DiseasesNeoadjuvant TherapyNeoplasm MetastasisCarcinoma, Non-Small-Cell LungRisk FactorsBacterial InfectionsFluorouracilAnti-Bacterial AgentsLeukopeniaAnthracyclinesCohort StudiesNauseaKaplan-Meier EstimateEpirubicinNeoplasm Recurrence, LocalAntimetabolites, AntineoplasticSalvage TherapyRisk AssessmentLymphoma, Non-HodgkinOpportunistic InfectionsImmunocompromised HostAntibiotic ProphylaxisMethotrexateUnited StatesChild MortalityAge FactorsDrug Resistance, NeoplasmLength of StayMucositisDisease ProgressionAdenocarcinomaProportional Hazards ModelsVomitingRecurrenceBacteremiaPenicillanic AcidAdministration, OralLeukocyte CountInfant, NewbornOxonic AcidTegafurMitoxantroneMultivariate AnalysisLeucovorinOvarian NeoplasmsIncidenceFeasibility StudiesMaternal MortalityRandomized Controlled Trials as TopicAntineoplastic Agents, AlkylatingInfectionStomach Neoplasms
Complication of chemotherapyManagement of febrile neutropeniaMajor cause of morbidityRegimensIncidenceHigh morbidity and mortaProphylaxisAdjuvant chemotherapyCancer chemotherapySevereRadiotherapyCytotoxic chemotherapyMyelosuppressive chemotherapyOutcomesComplicationsToxicityDrug-inducedSurvivalCisplatinStem cell transplantCONCLUSIONSOutcomeSystemic chemotherapyProphylacticDuration and severityIntensive chemotherapyTreatmentComorbiditiesClinicalColorectal cancerInitiationFeverSupportive careSurgical resectionInfectionsAdverse eventsPatients treatedPeripheralEfficacyCombinationOverall mortalityPatientTumorNSCLCTherapeuticPartial responsePersistent
Complication of chemotherapy2
Management of febrile neutropenia2
  • The objective of this protocol was to develop a reference tool for the evaluation and management of febrile neutropenia in a fourth-level cancer hospital in Ecuador and provide a guideline for a timely and adequate care of cancer patients. (ijpsonline.com)
  • The current system of management of febrile neutropenia involves administration of prophylactic antimicrobials and hematopoietic growth factor supplements (granulocyte colony stimulating factor G-‐ CSF). (biomedgrid.com)
Major cause of morbidity1
Regimens10
  • Docetaxel-based chemotherapy regimens have substantially improved survival and recurrence rates for cancer patients. (hindawi.com)
  • Safety profile of docetaxel regimens includes toxicities, particularly a high risk of neutropenia and febrile neutropenia. (hindawi.com)
  • Systemic adjuvant chemotherapy with anthracycline- and taxane-containing regimens has become the standard first line treatment for early and metastatic breast cancer [ 5 ], with large phase III randomized trials showing extremely high long-term disease-free survival and overall survival rates (resp. (hindawi.com)
  • In fact, reducing the planned dose intensity of systemic adjuvant chemotherapy regimens by as little as 15% has been shown to significantly reduce time to progression and overall survival rates in women with metastatic breast cancer [ 5 ]. (hindawi.com)
  • G-CSFs have been shown to reduce overall mortality risk [ 8 , 11 ], reduce the incidence of other adverse events (grade 2 or greater anaemia, asthenia, anorexia, myalgia, nail disorders, and oral mucositis) associated with docetaxel-based chemotherapy regimens, and increase health related quality of life and consequently treatment compliance [ 8 , 12 ]. (hindawi.com)
  • PURPOSE: Clinical practice guidelines recommend the use of all approved granulocyte colony-stimulating factors (G-CSFs), including filgrastim and pegfilgrastim, as primary febrile neutropenia (FN) prophylaxis in patients receiving high- or intermediate-risk regimens (in those with additional patient risk factors). (bvsalud.org)
  • Data collected included the type of malignancy, chemotherapy regimens, and patient comorbidities. (jhoponline.com)
  • Recommendations from the NCCN and from the American Society of Clinical Oncology and the published literature regarding regimens associated with febrile neutropenia were used to determine appropriate therapy. (jhoponline.com)
  • Patients in Europe with MSI-H/dMMR colorectal cancer have had only chemotherapy-containing regimens available to them in the first-line treatment setting and have historically faced poor outcomes," said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories. (merck.com)
  • 7 , 8 , 10 , 11 However, the rates of chemotherapy-induced FN reported in RCTs vary considerably for commonly used chemotherapy regimens. (jnccn.org)
Incidence14
  • Granotax was a prospective, open label, multicentre, national phase IV study that evaluated the incidence and severity of neutropenia in adult patients with solid tumors being treated with a docetaxel-based regimen while receiving the GCSF lenograstim. (hindawi.com)
  • Among the 394 enrolled patients the incidence of grade 3-4 neutropenia was 16.2% and of febrile neutropenia was 1.5%, far lower than the reported 85-100% and 30-40% incidence without G-CSFs. (hindawi.com)
  • The low incidence of adverse effects and chemotherapy dose changes, delays, and withdrawals supports the use of lenograstim as effective primary prophylaxis in South African patients being treated with a docetaxel-based regimen. (hindawi.com)
  • Neutrophils play a vital role in protecting against infection, so the duration and severity of neutropenia directly correlate with the total incidence of all infections, including those that are life threatening. (medscape.com)
  • METHODS: To assess the relationship between G-CSF prophylaxis and incidence of FN/infection in week 1 versus beyond week 1 of the first chemotherapy cycle, a retrospective study was conducted using Medicare claims from 2005 through 2020 among patients with breast cancer initiating high-risk chemotherapy. (bvsalud.org)
  • The duration and severity of neutropenia directly correlate with the total incidence of all infections and of those infections that are life threatening. (medscape.com)
  • The European Society for Medical Oncology (ESMO, 2016) reported an incidence of approximately 8 cases of FN per 1000 patients who received chemotherapy[ 1 ]. (ijpsonline.com)
  • GLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide. (neoplasiaresearch.com)
  • 10 ] reported a reduced incidence (25.5%) of grades 3 and 4 neutropenia and no cases of FN in a phase I/II trial of biweekly DCF (bDCF) regimen for metastatic esophageal cancer without a decrease in antitumor activity of the standard DCF therapy. (biomedcentral.com)
  • Although the incidence of acute nonlymphocytic leukemia is increased in PV, the incidence of acute leukemia in patients not exposed to chemotherapy or radiation therapy is low. (basicmedicalkey.com)
  • Neupogen is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. (medicines.org.uk)
  • In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 × 10 9 /l, and a history of severe or recurrent infections, long term administration of Neupogen is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. (medicines.org.uk)
  • The primary outcome of the study was to assess the incidence of bacteremia during periods of neutropenia. (jhoponline.com)
  • Childhood leukemia is the most common form of pediatric cancer in the United States, accounting for nearly 1 of 3 cancers, with an incidence rate of 4.8 per 100,000 persons based on data from 2016 to 2020. (jhoponline.com)
High morbidity and morta3
Prophylaxis5
  • Two cohorts were compared based on G-CSF prophylaxis within 3 days following chemotherapy initiation. (bvsalud.org)
  • Adults who had a diagnosis of cancer and received G-CSFs as prophylaxis for febrile neutropenia were included in this analysis. (jhoponline.com)
  • The results demonstrated that 47.22% and 8.2%, respectively, of G-CSF administrations did not have an indication supported by guideline recommendations for administering filgrastim and pegfilgrastim as prophylaxis for febrile neutropenia. (jhoponline.com)
  • Levofloxacin is the standard antibiotic of choice based on studies that showed lower rates of bacteremia with levofloxacin compared with clinician-directed prophylaxis. (jhoponline.com)
  • To evaluate the rate of bacteremia and the presence of fluoroquinolone resistance in pediatric patients with AML, with relapsed ALL, or undergoing HSCT who are receiving levofloxacin prophylaxis compared with no prophylaxis. (jhoponline.com)
Adjuvant chemotherapy2
  • In view of old age we started single agent capecitabine 1000 mg/m 2 twice daily for 14 days with 1 week off as adjuvant chemotherapy for total 6 months. (jbclinpharm.org)
  • Background: Despite a potentially curative treatment, the prognosis after upfront surgery and adjuvant chemotherapy for patients with resectable pancreatic ductal adenocarcinoma (PDAC) is poor. (unav.edu)
Cancer chemotherapy5
  • Febrile neutropenia is a common and serious complication of cancer chemotherapy. (ijpsonline.com)
  • One of the major side effects of cancer chemotherapy is myelosuppression leading to an obligate period of neutropenia. (biomedgrid.com)
  • Neutropenia is a serious adverse effect frequently associated with cancer chemotherapy (1,7). (biomedgrid.com)
  • Neutropenia and its complications, including febrile neutropenia (FN), represent major toxicities associated with cancer chemotherapy, resulting in considerable morbidity, mortality, and costs. (jnccn.org)
  • Neutropenia and its complications represent the major dose-limiting toxicities associated with systemic cancer chemotherapy and is associated with considerable morbidity, mortality, and cost. (jnccn.org)
Severe6
Radiotherapy9
  • Complete surgical resection of the tumor and preoperative radiotherapy and chemotherapies can be used for non-metastatic RPS. (biomedcentral.com)
  • This report describes a case of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma that was favorably controlled by debulking surgery followed by combination chemotherapy and radiotherapy. (biomedcentral.com)
  • Multimodal therapy with debulking surgery, combination chemotherapy and radiotherapy controlled a rapidly progressive retroperitoneal pleomorphic leiomyosarcoma. (biomedcentral.com)
  • Maintaining dose intensity of the chemotherapy and radiotherapy might contribute to overall tumor control. (biomedcentral.com)
  • Multimodal therapy incorporating surgery, radiotherapy, and chemotherapy is thus expected to improve survival in patients with RPS. (biomedcentral.com)
  • Traditionally, the treatment of hematological malignancies is administrated by chemotherapy, radiotherapy, and stem cell transplantation. (hindawi.com)
  • In limited-stage SCLC, the overall survival rate has been significantly improved by adding dose-hyperfractionated thoracic radiotherapy and prophylactic cranial irradiation to systemic chemotherapy. (ersjournals.com)
  • This staging system was used to select the appropriate treatment regimen: chemotherapy in combination with thoracic radiotherapy in patients with LS-SCLC, and chemotherapy alone in patients with ES-SCLC. (ersjournals.com)
  • This combination of chemotherapy and radiotherapy has a special role in tumor down staging and in sphincter preservation for lower rectal tumors. (wjgnet.com)
Cytotoxic chemotherapy5
  • Cytotoxic chemotherapy often induces febrile neutropenia and may lead to serious complications including mortality. (ijpsonline.com)
  • The safety and efficacy of Neupogen are similar in adults and children receiving cytotoxic chemotherapy. (medicines.org.uk)
  • The first dose of Neupogen should be administered at least 24 hours after cytotoxic chemotherapy. (medicines.org.uk)
  • Following induction and consolidation treatment for acute myeloid leukaemia the duration of treatment may be substantially longer (up to 38 days) depending on the type, dose and schedule of cytotoxic chemotherapy used. (medicines.org.uk)
  • In patients receiving cytotoxic chemotherapy, a transient increase in neutrophil counts is typically seen 1 to 2 days after initiation of Neupogen therapy. (medicines.org.uk)
Myelosuppressive chemotherapy2
Outcomes4
  • 2,3 Kuderer and colleagues estimated a 9.5% (95% confidence interval, 9.5%-9.8%) direct mortality risk for patients with cancer who were hospitalized with febrile neutropenia.2 Suboptimal chemotherapy treatment may affect patient outcomes and the overall efficacy of cancer management. (jhoponline.com)
  • Conclusions: Pharmacokinetically-guided dose adjustment of standard chemotherapy treatments might improve survival outcomes in patients with pancreatic ductal adenocarcinoma. (unav.edu)
  • In this article, we explore the survival rate of children with AML, shedding light on the progress and advancements in medical science that have improved outcomes for these brave fighters. (askthenurseexpert.com)
  • Identification of patients at a high individual risk for FN and its consequences may offer the potential for optimal chemotherapy delivery and patient outcomes. (jnccn.org)
Complications4
Toxicity1
Drug-induced1
  • Death before 30 days after neutrophil recovery occurred in five (3%) participants in the short treatment group: two due to progressive leukaemia, two due to candidaemia, and one due to Enterococcus faecium bacteraemia and drug-induced pneumonitis. (amsterdamumc.org)
Survival13
  • Furthermore, lenograstim may increase the patient's exposure to chemotherapy allowing patients to receive optimal dosing and duration of treatment, benefitting survival. (hindawi.com)
  • Nevertheless, treatment options have substantially improved survival rates. (hindawi.com)
  • Lentinan, (1, 3)-glucan purified from Shiitake mushrooms, has been reported to improve the overall survival of cancer patients receiving chemotherapy. (neoplasiaresearch.com)
  • Medical records were retrospectively reviewed to determine the objective response rate (ORR), disease control rate, overall survival, and adverse effects. (neoplasiaresearch.com)
  • Although, historically, chemotherapy was used for palliation of symptoms, during the last few years the median overall survival of patients with advanced CRC has been substantially increased from 12 months to about 21-22 months when all of the available chemotherapeutic agents are administered [ 3 ]. (biomedcentral.com)
  • However in this study the effect of the combination on survival and response rate was modest, reflecting the more advanced stage of the disease in such patients. (biomedcentral.com)
  • The European Commission's approval of KEYTRUDA plus chemotherapy for the treatment of certain patients with esophageal and HER2-negative GEJ cancer provides a new option in the first-line setting that has shown significant improvements in progression-free and overall survival. (merck.com)
  • The 2-year and 5-year survival rates were 72% and 55% in patients with LD and 43% and 0% in patients with extensive disease, respectively. (the-medical-dictionary.com)
  • Response rates in extensive disease (ED) range from 51 to 78%, including a 7 to 13% rate of complete response (CR) and a median survival of 8 to 9 months. (the-medical-dictionary.com)
  • In patients with limited disease (LD), the CR rate is 16 to 18%, with a median survival of 11.7 to 12.4 months. (the-medical-dictionary.com)
  • If left untreated, patients with SCLC rarely survive longer than a few months 5 , but chemotherapy dramatically prolongs survival compared to the best supportive care 6 . (ersjournals.com)
  • However, overall survival rates have improved significantly in recent years due to advancements in treatment options. (askthenurseexpert.com)
  • Based on such backgrounds, no standard first-line chemotherapy has been established and an unmet need exists for prolongation the survival time in AGC patients with SPM. (biomedcentral.com)
Cisplatin1
Stem cell transplant1
  • Purpose: To determine the tolerability and feasibility of double-cycle, high-dose chemotherapy followed by peripheral blood stem-cell transplantation (PBSCT) after conventional chemotherapy or chemoradiotherapy for small cell lung cancer (SCLC). (the-medical-dictionary.com)
CONCLUSIONS1
  • CONCLUSIONS: Overall, the rates of chemotherapy-related FN and infection in week 1 of the first chemotherapy cycle are similar for patients receiving and not receiving G-CSF, suggesting continued risk in week 1 despite prophylactic G-CSF. (bvsalud.org)
Outcome5
  • These improvements in outcome are very welcome, yet they do have associated substantial toxicities, especially a moderate-to-high risk of neutropenia or febrile neutropenia (FN) [ 8 ]. (hindawi.com)
  • Furthermore, they can lead to delays and dose reductions in chemotherapy treatment, thereby potentially compromising the efficacy of chemotherapy and, consequently, patient outcome [ 10 ]. (hindawi.com)
  • The primary outcome was FN or infection, defined as hospitalization with neutropenia, fever, or infection diagnosis. (bvsalud.org)
  • Unadjusted and regression-adjusted proportions of patients experiencing each outcome during week 1 versus beyond week 1 of the first chemotherapy cycle were compared. (bvsalud.org)
  • This has important clinical implications as, in contrast to advanced-stage NSCLC, chemotherapy can also be offered to patients with SCLC and a poor or bad performance status (World Health Organization performance status of 2-3), since a rapid amelioration of the patient's symptoms and general condition can be expected together with an improved outcome 7 . (ersjournals.com)
Systemic chemotherapy1
  • The risk of FN in patients receiving systemic chemotherapy has generally been based on the rates of FN in patients eligible for randomized controlled clinical trials (RCTs). (jnccn.org)
Prophylactic1
  • Prophylactic antibiotics are often used in pediatric patients for the treatment of acute myeloid leukemia (AML) and relapsed acute lymphoblastic leukemia (ALL), and for those undergoing hematopoietic stem cell transplant (HSCT) who are receiving intensive chemotherapy. (jhoponline.com)
Duration and severity1
Intensive chemotherapy1
Treatment25
  • There is strong and consistent clinical evidence to show that granulocyte-colony stimulating factors (G-CSFs) reduce the risk of chemotherapy-induced neutropenia and therefore complicated neutropenia and can be used to maintain chemotherapy at the desired dose intensity or density and minimize delays in treatment [ 11 ]. (hindawi.com)
  • In all, 4.66% of pegfilgrastim treatment was administered on the same day as chemotherapy administration, despite guideline recommendations for a 24- to 72-hour wait period between the administrations of chemotherapy and G-CSF. (jhoponline.com)
  • Guideline recommendations for the prevention and/or treatment of patients with febrile neutropenia have been published by the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the Infectious Diseases Society of America (IDSA). (jhoponline.com)
  • This document compiles updated information available on the definition, risk factors, evaluation methods, treatment and special situations in cancer patients with febrile neutropenia. (ijpsonline.com)
  • Repeated infections results in prolonged periods of hospitalisation, delay in treatment and chemotherapy dose reductions. (biomedgrid.com)
  • The current treatment regime provides only a small reduction in infection-‐ related mortality. (biomedgrid.com)
  • Here we are reporting rare case series of capecitabine induced marrow aplasia in patients of colorectal cancer during adjuvant treatment. (jbclinpharm.org)
  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. (neoplasiaresearch.com)
  • Reprogramming is a promising treatment, which redifferentiates T-induced pluripotent stem cells (T-IPSCs) into naïve and cytotoxic T cells or dedifferentiates within their own lineage [ 13 ]. (hindawi.com)
  • Interpretation: Early discontinuation of carbapenem treatment in patients with febrile neutropenia of unknown origin does not result in increased treatment failure. (amsterdamumc.org)
  • However, because secondary analyses suggested that serious adverse events and all-cause mortality occurred more often in patients who are persistantly febrile the short treatment group, we recommend vigilance for non-susceptible pathogens and early resumption of empirical therapy in patients who are deteriorating. (amsterdamumc.org)
  • Immunosuppression induced by a preoperative chemotherapeutic treatment can increase postoperative infections. (biomedcentral.com)
  • KEYTRUDA plus chemotherapy is the first anti-PD1 therapy approved in Europe in this first-line setting, allowing these patients to be treated with immunotherapy earlier in the course of their treatment," said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. (merck.com)
  • If fever persists 72-96 hours after treatment with broad-spectrum antibacterial antibiotics during neutropenia, invasive fungal infection may be suspected and treated empirically with antifungal agents [ 1 - 3 ]. (biomedcentral.com)
  • Although SCLC is very chemoradiosensitive and high response rates are obtained with treatment, relapse rates are high and the prognosis remains very poor. (ersjournals.com)
  • The first-line treatment of ES-SCLC currently consists of chemotherapy with a platinum derivative and etoposide, a combination that was first reported to be effective in the treatment of SCLC in 1985 8 , 9 . (ersjournals.com)
  • ONUREG is a nucleoside metabolic inhibitor indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy ( 1 ). (nih.gov)
  • Neupogen is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 × 10 9 /l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. (medicines.org.uk)
  • Following established chemotherapy for solid tumours, lymphomas, and lymphoid leukaemia, it is expected that the duration of treatment required to fulfil these criteria will be up to 14 days. (medicines.org.uk)
  • 14 Variation in chemotherapy treatment intensity and intent as well as additional risk factors, including patient characteristics and comorbidities, have been identified for chemotherapy-induced FN. (jnccn.org)
  • HYCAMTIN® for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. (globalrph.com)
  • HYCAMTIN for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. (globalrph.com)
  • On the other hand, adaptation of patients to chemotherapy should be carefully judged before treatment initiation because an aggressive disease course can immediately change the condition of patients into a non-adaptive state to chemotherapy. (biomedcentral.com)
  • Behrendt G, Schneider S, Brodt HR, et al: Influence of antimicrobial treatment on mortality in septicemia. (karger.com)
  • Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. (karger.com)
Comorbidities1
  • People exposed to radiation may be divided into "low-risk" and "high-risk" susceptibility groups, based on degree of neutropenia and the presence of comorbidities. (msdmanuals.com)
Clinical4
  • Management of Chemotherapy Induced Neutropenia - an Unmet Clinical Need. (biomedgrid.com)
  • The clinical response rate of the bDCF group was significantly higher than that of the DCF group (86.4 vs. 62.2%, p = 0.047). (biomedcentral.com)
  • En mayo de 2007 obtuve el Certificate of Training in Molecular Biological Techniques en el Department of Molecular Biology y desde Junio de 2008 a Junio de 2009 completé el Certificate in Clinical Research en el Center for Translational Science Activities en Mayo Clinic College of Medicine, Rochester Minnesota. (unav.edu)
  • Un 40% de esos trabajos han sido publicados en revistas del primer cuartil entre las que destacan New England Journal of Medicine, Lancet, Lancet Infectious Diseases, Clinical Infectious Diseases, Clinical Microbiology Reviews, Antimicrobial Agents and Chemotherapy, Journal Clinical Microbiology, Journal Antimicrobial Chemotherapy, Mayo Clinic Proceedings y Malaria Journal. (unav.edu)
Colorectal cancer1
  • From the above three cases, it is evident that capecitabine causes hypocellular marrow, which we are using as adjuvant or palliative chemotherapy in colorectal cancer. (jbclinpharm.org)
Initiation1
Fever4
Supportive care2
  • Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. (neoplasiaresearch.com)
  • This article reviews and summarizes FN modeling studies and the opportunities for personalizing supportive care in patients receiving chemotherapy. (jnccn.org)
Surgical resection1
  • They are unlikely to have metastasized and therefore the standard tumor management is surgical resection, coupled with chemotherapy. (wikipedia.org)
Infections1
Adverse events1
  • An increase in DCF-induced adverse events is anticipated in elderly patients, patients with organ disorders, and patients suffering from malnutrition. (biomedcentral.com)
Patients treated1
  • At the study's final analysis, there was not an improvement in OS for patients treated with KEYTRUDA plus LENVIMA with chemotherapy compared to KEYTRUDA with chemotherapy. (streetinsider.com)
Peripheral1
Efficacy2
  • However, neutropenia is detected in these patients only after the onset of infection limiting the efficacy of these therapeutic interventions. (biomedgrid.com)
  • Wang H, Cai Y, Zheng Y, Bai Q, Xie D, Yu J. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. (neoplasiaresearch.com)
Combination3
  • Combination chemotherapy, consisting of doxorubicin and ifosfamide, was successfully administered for six cycles while maintaining dose intensity. (biomedcentral.com)
  • Although neutropenia (grade ≥ 3) occurred more frequently with combination therapy, both treatments in this study were tolerable. (biomedcentral.com)
  • The standard first-line chemotherapy for patients with erb-b2 receptor tyrosine kinase 2 (ERBB2, also known as HER2)-negative advanced GC (AGC) in Japan is a combination therapy with fluoropyrimidine plus platinum (e.g. (biomedcentral.com)
Overall mortality1
  • However, a meta-‐ analysis has shown that overall mortality is not influenced significantly by the use of antibiotics or growth factors (4,6). (biomedgrid.com)
Patient2
  • First patient is 51 year old male with locally advanced rectal cancer, developed persistent pancytopenia after 5th cycle of chemotherapy. (jbclinpharm.org)
  • The patient developed an acute febrile illness in August 2012 during a 1-month vacation in New Mexico. (cdc.gov)
Tumor2
  • A high proliferation rate of the tumor cells was also seen on immunohistochemical analysis (Figure 2 ). (biomedcentral.com)
  • This indication is approved under accelerated approval based on tumor response rate and durability of response. (businesswire.com)
NSCLC1
  • Response rates in SCLC are much higher than in NSCLC, although MS remains poor. (ersjournals.com)
Therapeutic1
  • There was no significant between-group difference in the postoperative morbidity rate (bDCF 45.5% vs. DCF 32.4%) or in the histological therapeutic effect. (biomedcentral.com)
Partial response1
  • The best objective response was a partial response, and the chemotherapy was well tolerated. (biomedcentral.com)
Persistent1